Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Several technologies for hemoglobinopathies are being transferred to commercial partners
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
